€414.45
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 3.140% | 5.808% | 5.970% | 4.951% | 5.808% | 52.064% | 118.315% |
| Incyte Corp. | 4.360% | 12.420% | 7.518% | 33.767% | 12.420% | 24.677% | 29.009% |
| Regeneron Pharmaceuticals Inc. | 4.730% | 4.916% | 12.808% | -1.501% | 4.916% | 0.520% | 77.432% |
| Amgen Inc. | 3.740% | 4.426% | 3.265% | 15.473% | 4.426% | 13.216% | 53.360% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating the financial position of Vertex Pharmaceuticals Inc. (symbol: VRTX), it is evident that the company exhibits robust financial health, especially for a player in the Biotechnology & Medical Research sector. As observed from the provided financial statements, Vertex demonstrates strong revenue growth, impressive profitability, and significant cash reserves. This overall positive trend is accompanied by notable investment in research and development, which is critical for sustaining innovation in the biotech field. However, like any investment, a deeper dive into the various financial metrics is essential to identify both advantages and drawbacks.
Strong Revenue Generation: Vertex reported a total revenue of approximately $9.87 billion for 2023, showcasing healthy growth compared to previous years. The quarterly revenue growth rate of 13.3% indicates consistent demand for its products, which is promising for future sales and market expansion.
Impressive Profit Margins: The profit margin stands at around 39.5%, highlighting Vertex's ability to convert sales into profits effectively. Coupled with an operating margin of 45.2%, it reflects efficient management of operational expenses relative to revenue.
Comments
News
Why a 63% Vertex Selloff Didn’t Scare Off a New $13 Million Investor
On November 13, New York City-based Hyperion Capital Advisors disclosed a new position in Vertex (NASDAQ:VERX), acquiring 540,000 shares valued at approximately $13.39 million.
According to a filing
Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026?
CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than 40% this year, in three of the past five years it has fallen by more than
2 Healthcare Stocks to Buy Ahead of the New Year
Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors should avoid the sector altogether. Many healthcare companies appear to